Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
---|
06/07/1995 | CN1103316A Cyclodextrin and polymer-based drug delivery system |
06/07/1995 | CN1103315A Improved methods for the determination and adjustment of prolactin daily rhythms |
06/07/1995 | CN1103295A Oral nutrient ribonucleic acid liquid and its preparing method |
06/07/1995 | CN1103294A "Kangle" three-in-one safety agent |
06/07/1995 | CN1103293A Ethacridine use and method |
06/07/1995 | CN1103292A Analgin nasal drops |
06/07/1995 | CN1103291A Preparation for skin and mucous membrane |
06/07/1995 | CN1103290A Pharmaceutical preparation |
06/07/1995 | CN1103289A Opioid formulations having extended controlled release |
06/07/1995 | CN1103288A Local anaesthetic and its preparing method |
06/07/1995 | CN1028760C Process for preparing sequence of antidirection direction, antimessenger RNA oligonuclectides of alpha TNF |
06/07/1995 | CN1028759C Substituted thiacycloalkeno |2,3-b¨ pyridines, method of preparation, compositions and method of use |
06/07/1995 | CN1028758C Pyrazolopyrimidinone antianginal agents |
06/07/1995 | CN1028757C Process for preparing heterocyclic derivatives |
06/07/1995 | CN1028756C Pryidyl-and pyrimidyl derivatives |
06/07/1995 | CN1028755C Azole derivate, manufacturing method and application thereof |
06/07/1995 | CN1028754C Quinoline derivatives, their production and use |
06/07/1995 | CA2137443A1 Thienothiazinderivatives, process for their preparation and their use |
06/07/1995 | CA2137213A1 Imidazopyridines |
06/06/1995 | US5422393 Natriuretic hormone |
06/06/1995 | US5422374 Oral administration of ubidecarenone |
06/06/1995 | US5422373 Anti-atherosclerotic aryl compounds |
06/06/1995 | US5422372 Method of increasing intracellular accumulation of hydrophilic anionic agents using gemfibrizol |
06/06/1995 | US5422371 Contacting a cell with a fatty acid or fatty alcohol to prevent reduction of testosterone to 5a-dihydrotestosterone |
06/06/1995 | US5422370 Method of using 2-hydroxypropanoic acid (lactic acid) for the treatment of wrinkles |
06/06/1995 | US5422369 Topical treatment |
06/06/1995 | US5422368 With omega chain having a ring as end group, side effect reduction |
06/06/1995 | US5422367 Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents |
06/06/1995 | US5422366 Forming oxygen-scavenging metal chelate or metal complex-containing film over nail to deprive aerobic fungi of oxygen |
06/06/1995 | US5422365 Naphthalene compounds |
06/06/1995 | US5422363 Therapy of cancer, diabetes and vision disorders |
06/06/1995 | US5422362 Method to inhibit restenosis |
06/06/1995 | US5422359 α-aminoketone derivatives |
06/06/1995 | US5422358 Muscarinic receptor antagonists |
06/06/1995 | US5422357 Method of using oxatomide as antitussive agent |
06/06/1995 | US5422355 Composition for treating depression with (N-heteroaryl)alkylamines |
06/06/1995 | US5422354 Quinuclidine derivatives |
06/06/1995 | US5422353 Tetrahydropyridine derivatives |
06/06/1995 | US5422352 Administering a thermogenically effective dose of ephedrine and caffeine to reduce weight in humans |
06/06/1995 | US5422351 Antiallergens; antiinflammatory agents |
06/06/1995 | US5422350 Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use |
06/06/1995 | US5422349 Renin inhibitors |
06/06/1995 | US5422347 Fungicides, hair and skin disorders |
06/06/1995 | US5422346 Evaporative concentration to adjust degree of polymerization of pressed and assayed juice having cold water solubility and free from sesquiterpene lactones |
06/06/1995 | US5422345 Useful in diagnosing or treating herpes viral infections |
06/06/1995 | US5422344 Method of treating retroviral infections in mammals |
06/06/1995 | US5422343 Prophylactic and therapeutic composition for MRSA infection |
06/06/1995 | US5422342 A hydrolase inhibitor comprising a protected oligopeptides for treating fibrose of lungs, liver and skins, atherosclerosis |
06/06/1995 | US5422124 Pharmaceutical oral controlled release composition comprising small pellets of bile acids |
06/06/1995 | US5422119 Alternating dominance of estrogen and progestin in a patch regimen therapy to females; menopause |
06/06/1995 | US5422115 Methods of treatment and devices employing lithium salts |
06/06/1995 | US5422103 Wound healing agents for burns, bed sores; blended with dextran |
06/06/1995 | US5422102 Diclofenac or salt with nonionic polymer of hydroxypropyl and/or hydroxyethyl cellulose; percutaneous adsorption |
06/06/1995 | US5422101 Cholesterol lowering drink mix compositions |
06/06/1995 | US5422100 Method and product for treating skin afflictions |
06/06/1995 | US5422099 Compositions comprising vitamin D precursors and the use thereof |
06/06/1995 | US5422093 Administering to produce protoporphyrin IX which accumulates in rapidly growing cells and fluoresces after exposure to light; anticarcinogenic and -tumor agents; urogenital disorders |
06/06/1995 | US5421819 Medical probe device |
06/06/1995 | CA2044795C Dermatological composition based on an aqueous phase |
06/06/1995 | CA1335858C Polyanhydrides with improved hydrolytic degradation properties |
06/06/1995 | CA1335816C 4-pyridyl-1,3-dioxan-5-ylalkenoic acid derivatives |
06/06/1995 | CA1335813C Administration of monoamine acridines in cholinergic neuronal deficit states |
06/06/1995 | CA1335789C Fatty acid compositions |
06/06/1995 | CA1335788C Protein absorption enhancing agents |
06/04/1995 | CA2137186A1 Erythromycine derivatives, a process for their preparation and use as drugs |
06/04/1995 | CA2137029A1 Novel compounds |
06/04/1995 | CA2137028A1 Pharmaceutical compounds |
06/04/1995 | CA2136904A1 Excitatory amino acid receptor antagonists |
06/04/1995 | CA2136569A1 Nutritional compositions for management of nitrogen metabolism |
06/03/1995 | CA2136915A1 Substituted 2.beta.- morpholino-androstane derivatives |
06/03/1995 | CA2135088A1 Liver protectant composition |
06/02/1995 | CA2136789A1 Methods of inhibiting the effects of amyloidogenic proteins |
06/01/1995 | WO1995014791A1 Design of drugs involving receptor-ligand-dna interactions |
06/01/1995 | WO1995014777A1 p53-BINDING POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME |
06/01/1995 | WO1995014709A1 Side chain fluoro substituted 3-carboxysteroids |
06/01/1995 | WO1995014707A1 N-2 substituted purines |
06/01/1995 | WO1995014706A1 Pna-dna-pna chimeric macromolecules |
06/01/1995 | WO1995014697A1 Heterocyclic esters of rapamycin and pharmaceutical compositions containing them |
06/01/1995 | WO1995014696A1 Hindered esters of rapamycin and their use as pharmaceuticals |
06/01/1995 | WO1995014695A1 Novel furanodiazepines |
06/01/1995 | WO1995014694A1 Benzodiazepines |
06/01/1995 | WO1995014693A1 Imidazolinobenzodiazepines |
06/01/1995 | WO1995014691A1 NOVEL 9-HYDROXY-PYRIDO[1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES |
06/01/1995 | WO1995014687A1 Novel substituted thiosemicarbazonic acid esters |
06/01/1995 | WO1995014686A1 Novel substitued thiosemicarbazonethiones |
06/01/1995 | WO1995014685A1 Novel substituted thiosemicarbazone derivatives |
06/01/1995 | WO1995014684A1 Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones |
06/01/1995 | WO1995014683A1 Novel isoxazoline and isoxazole fibrinogen receptor antagonists |
06/01/1995 | WO1995014682A1 Isoxazoline compounds useful as fibrinogen receptor antagonists |
06/01/1995 | WO1995014681A1 Isoxazoline compounds as antiinflammatory agents |
06/01/1995 | WO1995014680A1 3-aryl-2-isoxazolines as antiinflammatory agents |
06/01/1995 | WO1995014676A1 3-acylaminobenzodiazepines |
06/01/1995 | WO1995014673A1 4,5-diphenylimidazole derivatives, their preparation and their use as acyl coenzyme a: cholesterol-0-acyl-transferase (acat) inhibitor |
06/01/1995 | WO1995014671A1 3-acylaminobenzazepines |
06/01/1995 | WO1995014670A1 Heterocyclic benzenesulfonylimine derivatives as inhibitors of il-1 action |
06/01/1995 | WO1995014669A1 Novel benzenesulfonylimine derivatives as inhibitors of il-1 action |
06/01/1995 | WO1995014667A1 Substituted indoles as phosphodiesterase type iv inhibitors |
06/01/1995 | WO1995014666A1 Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s) |
06/01/1995 | WO1995014662A1 26,28-methylene-1alpha,25-dihydroxyvitamin d2 compounds |
06/01/1995 | WO1995014657A1 Alpha-aryl or heteroaryl-substituted amide ester acat inhibitors |